Fulgent Genetics Inc $ 111.38 10.12 (9.99%)
Volume:
1,595,945
Avg Vol (1m):
2,294,843
Market Cap $:
2.70 Bil
Enterprise Value $:
2.63 Bil
PE Ratio:
55.15
PB Ratio:
14.03
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 27.32 | ||
| Equity-to-Asset | 0.76 | ||
| Debt-to-Equity | 0.02 | ||
| Debt-to-EBITDA | 0.04 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 26.43 | ||
| Beneish M-Score | 3.54 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 47.25 | ||
| Net Margin % | 35.31 | ||
| ROE % | 48.42 | ||
| ROA % | 40.95 | ||
| ROC (Joel Greenblatt) % | 239.65 | ||
| 3-Year Revenue Growth Rate | 9.3 | ||
| 3-Year EBITDA Growth Rate | -16 | ||
| 3-Year EPS without NRI Growth Rate | 72.9 |
FLGT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 55.15 | ||
| Forward PE Ratio | 21.46 | ||
| PE Ratio without NRI | 55.15 | ||
| PB Ratio | 14.03 | ||
| PS Ratio | 19.01 | ||
| Price-to-Operating-Cash-Flow | 420.29 | ||
| EV-to-EBIT | 41.22 | ||
| EV-to-EBITDA | 39.72 | ||
| EV-to-Revenue | 19.48 | ||
| Current Ratio | 3.39 | ||
| Quick Ratio | 3.08 | ||
| Days Inventory | 38.46 | ||
| Days Sales Outstanding | 244.95 | ||
| Days Payable | 163.58 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 14.03 | ||
| Price-to-Graham-Number | 5.86 | ||
| Earnings Yield (Greenblatt) % | 2.43 |